Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement

Dow Jones02:51

By Josh Beckerman

Sensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement.

The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks.

Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others.

Faeth is developing drugs that target tumor metabolism and signaling.

On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. "We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies," the company said at the time.

Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

February 18, 2026 13:51 ET (18:51 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2612423560?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-19 02:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612423560","market":"sh","top_or_hot":-1,"title":"Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> shares surged as it acquired Faeth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and entered an agreement for a $200 million private placement. \n</p>\n<p>\n  The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks. \n</p>\n<p>\n  Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others. \n</p>\n<p>\n  Faeth is developing drugs that target tumor metabolism and signaling. \n</p>\n<p>\n  On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time. \n</p>\n<p>\n  Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 13:51 ET (18:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sensei Biotherapeutics Shares Surge on Acquisition, Private Placement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSensei Biotherapeutics Shares Surge on Acquisition, Private Placement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-02-19 02:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SNSE\">Sensei Biotherapeutics</a> shares surged as it acquired Faeth <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> and entered an agreement for a $200 million private placement. \n</p>\n<p>\n  The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks. \n</p>\n<p>\n  Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others. \n</p>\n<p>\n  Faeth is developing drugs that target tumor metabolism and signaling. \n</p>\n<p>\n  On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time. \n</p>\n<p>\n  Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 18, 2026 13:51 ET (18:51 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SNSE","symbol_name":"Sensei Biotherapeutics, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2612423560","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612423560","pubTimestamp":1771440660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Sensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement.The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks.Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others.Faeth is developing drugs that target tumor metabolism and signaling.On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time.Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SNSE":"Sensei Biotherapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Sensei Biotherapeutics股价因收购和私募而飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SNSE":1.5},"content_text":"By Josh Beckerman \n\n\n \n\n\nSensei Biotherapeutics shares surged as it acquired Faeth Therapeutics and entered an agreement for a $200 million private placement. \n\n\n  The stock rose 177% to $25.32 and is up about 169% for the past 52 weeks. \n\n\n  Investors include B Group Capital, Balyasny Asset Management, Columbia Threadneedle Investments, Cormorant Asset Management, Fairmount, Logos Capital, RA Capital Management, Vivo Capital and others. \n\n\n  Faeth is developing drugs that target tumor metabolism and signaling. \n\n\n  On Oct. 17, cancer-focused Sensei reported results from the dose expansion portion of its Phase 1/2 trial evaluating solnerstotug. \"We believe solnerstotug's emerging dose-dependent activity in refractory 'hot' tumors, combined with a favorable tolerability profile, support its advancement into Phase 2 studies,\" the company said at the time. \n\n\n  Sensei said on Oct. 30 that it would discontinue development of solnerstotug, review strategic alternatives and implement a workforce reduction. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 18, 2026 13:51 ET (18:51 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2612423560","isCrawlerRequest":true}